The American Academy Of Pain Medicine

The physicians' voice in pain medicine
  • Foundation
  • Store
  • Career Center
  • Press
  • Join-Renew
Search: Go
Member Login: Login

Enter the AAPM
Members' Community

  • Member Center
  • Patient Center
  • Library
  • Advocacy
  • Practice Management
  • CME
  • Annual Meeting
  • Safe Prescribing Resources
  • PI-CME Portal

Library

Home > Library > For Pain Researchers > 2013 Poster Abstracts
  • Research in the News
  • For Pain Researchers
    • 2013 Poster Abstracts
    • 2012 Poster Abstracts
    • Research Resources
    • Research Presentations
    • Search Clinical Trials (NIH)
    • Register a Clinical Trial (NIH)
    • Medline - US National Library of Medicine
  • Clinical Guidelines and Resources
  • Pain Facts
  • Archives
  • FDA Updates, Recalls and Warnings
  • Presented at the 2013 AAPM Annual Meeting « Back

    193

    Microwave Ablation Under Local Anesthesia of Bone and Soft-Tissue Tumors: Preliminary Results

    Adrian Kastler, MD, adriankastler@gmail.com1, Hussein Alnassan1, Sébastien Aubry, MD PhD1, Bruno A. Kastler, MD, PhD1, (1) Centre Hospitalier Universitaire, Besançon, Franche Comté, France

    Objectives: To evaluate the feasibility and efficacy of percutaneous microwave ablation (MWA) under CT guidance in the management of refractory pain in bone and soft tissue tumors. Material and Methods: 20 MWA were performed in 13 adult patients using an Acculis MTA-2 Generator, 4,5GHz with a 17 gauge antenna. Topography of lesions were as follows: 15 bone lesions (rib: 8, spine: 3, sacrum: 2, scapula 1, clavicle 1) and 5 soft tissue lesions (subcutaneous: 2, axillary: 1, peri-scapular: 1, subclavicular: 1). 12 of 15 bone lesions were osteolytic. 16 of 20 ablated lesions were metastases (Lung: 8, Leiomyosarcoma: 3, Thyroid: 2, Kidney: 1, Prostate: 2). All procedures were performed with CT guidance under local anesthesia and nitrous oxide. Follow-up was performed either by contrast ultrasound or MRI. Pain prior procedure, immediately after and distance was assessed using a VAS pain score. Results: Lesion size ranged from 12 mm to 120 mm. Technical success was 100%. Mean ablation time was 4.85 minutes (1-13) with an average of 4.2 cycles per ablation lasting from 30 seconds to 3 minutes with a mean ablation power of 60W Mean VAS before procedure was 7.29/10. Immediate pain relief was greater than or equal to 50% in 19/20 cases with and lasting for an average of 4.36 months (range 0.5-15months). We report one case of secondary abcess at ablation site requiring further management (drainage). Conclusions: When other therapies provide insufficient pain relief, percutaneous MWA treatment appears to be a feasible and effective technique for the management of refractory pain in bone and soft-tissue tumors. Ablation time appears to be highly reduced compared to radiofrequency ablation.

    Funding: None

  • Home
  • Member Center
  • Patient Center
  • Library
  • Advocacy
  • Practice Management
  • CME
  • Annual Meeting
  • Contact Us
  • Members' Community
  • Privacy Policy
  • Sitemap
Close

Members Only Alert Message

Please login to access AAPM member only information.
Forgot your login information?

Sign Up Today!

Join AAPM today and be part of the primary organization for physicians practicing in the specialty of pain medicine and begin accessing AAPM member benefits. 

Join
Or

Log In

Please log in and you will be redirected to the requested page.

Log In